NEXT GENERATION FERTILITY TECH
Separating Winning
Sperm in Alliance
with Nature
ABOUT
Molecule 46
Molecule 46 is a biotech spin-off offering a unique patented technology for the separation of undamaged sperm to be used in human assisted reproduction and solve the infertility problem related to poor sperm quality.
This technology is equally applicable to animal breeding strategies. The company brings an innovative approach with a strong IP position and robust scientific research. The new technology and clear regulatory pathway are strengthened by an internationally recognised founder with a strong academic track record and founder/market fit for a large and fast-growing market.
This project offers real social impact as well as endorsement from buyers and users.
HUMAN
Application
ASSISTED REPRODUCTION
Increase of sperm quality
and fertilization success
CRYOPRESERVATION
Personalised approach
to oncology patients
ONCOFERTILITY
Personalised approach
to oncology patients
PREVENTIVE MEDICINE
Diagnostics and screening
of reproductive health
ANIMAL
Application
LIVESTOCK BREEDING
Healthy sperm for
efficient insemination
ENDANGERED SPECIES CONSERVATION
Undamaged sperm for
ZOO-based fertility programs
HUMAN
Application
ASSISTED
REPRODUCTION
Increase of sperm quality
and fertilization success
CRYOPRESERVATION
Personalised approach
to oncology patients
ONCOFERTILITY
Personalised approach
to oncology patients
PREVENTIVE MEDICINE
Diagnostics and screening
of reproductive health
ANIMAL
Application
LIVESTOCK BREEDING
Healthy sperm for
efficient insemination
ENDANGERED SPECIES
CONSERVATION
Undamaged sperm for
ZOO-based fertility
programs
SUCCESS to date
STRONG IP POSITION
AND PROACTIVE IP STRATEGY
-
Exclusive rights to core IP assets,
-
Czech and European patents granted
-
New PCT filings under preparation
-
US Patent pending
-
European Registered Trademark
SCIENTIFIC EVIDENCE
& PROOF-OF-MARKET
- Technology backed by 15 years of research
- In-vitro benchmarking studies completed
- Two prototype iterations leading to MVP 2.0
- Molecule 46 technology currently at level TRL 3 (human) / TRL 4 (animal)
- Endorsement by seven leading IVF clinics in the Czech Republic
- Collaboration with three leading European livestock breading companies
- Twenty more early adopter leads in the pipeline
LOCAL & INTERNATIONAL
NON-DILUTIVE FUNDING
- CzechInvest Technology Incubation
- Central Bohemian Innovation Center
- EIT Health
- European and US technology grant applications under submission (€1M+)
PEOPLE
-
Scientific Advisory board selected, including a Nobel prize laureate
-
R&D team in place
-
Key roles and responsibilities identified pending expansion
AWARDS and MEDIA
2025
Bronze Award at Company of the Year, Capital City Prague
Silver Award at Start-up Disrupt Innovations United
Finalist at InnoStars Awards EIT Health
Innovations United, Key-note and panellist
2024
Gold Award at Start-up Accelerator,
Central Bohemian Innovation Center
Forbes, The most influential women of the Czech Republic
Forbes, Invited speaker at The Next Big Thing
Nominated for The Czech Scientist
of the Year – Innovation Technology
and EY Entrepreneur of the Year
2023
Forbes, Top Czech women scientist 2023
Ministry of Foreign Affairs, Czech women in World Science, TV and newspaper coverage, Czech Consulate, Istanbul, Turkey
2022
The Guardian, The Telegraph, BBC Science focus, Daily Mirror, The Tribune, Yahoo news
Czech TV, Prima CNN, Czech Radio,
and newspaper coverage
Czech Grant agency award for outstanding grant achievement
2021
Czech Press Office release,
The utilization of CD46 protein can accelerate the process of artificial insemination.
PROUD to cooperate with
